Dorota PozarowskaDepartment of Ophthalmology, Medical University, Lublin, PolandAbstract: Glaucoma is one of the most common neuropathies of the optic nerve. An elevated intraocular pressure (IOP) is a well documented risk factor for the development and progression of this disease. Until now, IOP reduction is the only well documented successful method of glaucoma treatment. Among the many hypotensive drugs, prostaglandin analogs are proved to be the most potent antiglaucoma agents, with very few systemic side effects. A new prostanoid FP receptor analog, tafluprost, has been introduced into the medical treatment of glaucoma and ocular hypertension. Many studies have shown that it is an efficient IOP-lowering drug, and that it is safe and we...
Young Hoon HwangDepartment of Ophthalmology, Konyang University, Kim's Eye Hospital, Myung-Gok E...
. Purpose. To compare the ocular hypotensive effect of tafluprost with prostaglandin analogues (PGAs...
Purpose: Data are presented from ophthalmology clinics in Spain participating in the VISIONARY study...
Yang Liu, Weiming MaoDepartment of Cell Biology and Anatomy, North Texas Eye Research Institute, Uni...
Sitki Samet ErmişFaculty of Medicine, Balikesir University, Tip Fakültesi, Çagis...
Purpose: Increased intraocular pressure (IOP) is the most important modifiable risk factor for the d...
Ines Lanzl,1 Thomas Hamacher,2 Klaus Rosbach,3 Mohammed Osman Ramez,4 Robert Rothe,5 Eva Ružickov&aa...
Objectives: The aim of this study was to evaluate the safety of preservative-free tafluprost in newl...
Objectives: The aim of this study was to evaluate the safety of preservative-free tafluprost in newl...
Introduction: A non-interventional, multicenter, European, prospective evaluation of the effectivene...
Introduction: A non-interventional, multicenter, European, prospective evaluation of the effectivene...
Introduction: A non-interventional, multicenter, European, prospective evaluation of the effectivene...
Purpose: The benzalkonium chloride (BAK) content of tafluprost ophthalmic solution (Tapros®: taflupr...
Copyright © 2012 Stefano Ranno et al. This is an open access article distributed under the Creative ...
Luciano Quaranta,1,* Ivano Riva,1,* Andreas Katsanos,2 Irene Floriani,3 Marco Centofanti,4,† ...
Young Hoon HwangDepartment of Ophthalmology, Konyang University, Kim's Eye Hospital, Myung-Gok E...
. Purpose. To compare the ocular hypotensive effect of tafluprost with prostaglandin analogues (PGAs...
Purpose: Data are presented from ophthalmology clinics in Spain participating in the VISIONARY study...
Yang Liu, Weiming MaoDepartment of Cell Biology and Anatomy, North Texas Eye Research Institute, Uni...
Sitki Samet ErmişFaculty of Medicine, Balikesir University, Tip Fakültesi, Çagis...
Purpose: Increased intraocular pressure (IOP) is the most important modifiable risk factor for the d...
Ines Lanzl,1 Thomas Hamacher,2 Klaus Rosbach,3 Mohammed Osman Ramez,4 Robert Rothe,5 Eva Ružickov&aa...
Objectives: The aim of this study was to evaluate the safety of preservative-free tafluprost in newl...
Objectives: The aim of this study was to evaluate the safety of preservative-free tafluprost in newl...
Introduction: A non-interventional, multicenter, European, prospective evaluation of the effectivene...
Introduction: A non-interventional, multicenter, European, prospective evaluation of the effectivene...
Introduction: A non-interventional, multicenter, European, prospective evaluation of the effectivene...
Purpose: The benzalkonium chloride (BAK) content of tafluprost ophthalmic solution (Tapros®: taflupr...
Copyright © 2012 Stefano Ranno et al. This is an open access article distributed under the Creative ...
Luciano Quaranta,1,* Ivano Riva,1,* Andreas Katsanos,2 Irene Floriani,3 Marco Centofanti,4,† ...
Young Hoon HwangDepartment of Ophthalmology, Konyang University, Kim's Eye Hospital, Myung-Gok E...
. Purpose. To compare the ocular hypotensive effect of tafluprost with prostaglandin analogues (PGAs...
Purpose: Data are presented from ophthalmology clinics in Spain participating in the VISIONARY study...